Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries.
It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform.
The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.
It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products.
The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech.
It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors.
The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.
Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 30, 25 | -0.65 Increased by +39.67% | -0.74 Increased by +12.16% |
| Sep 17, 25 | -1.00 Increased by +5.60% | -0.73 Decreased by -36.99% |
| May 7, 25 | -0.94 Increased by +7.62% | - |
| Feb 10, 25 | -0.53 Decreased by -350.72% | - |
| Nov 11, 24 | -1.08 Decreased by -467.05% | - |
| Sep 10, 24 | -1.06 Decreased by -562.06% | - |
| May 9, 24 | -1.01 Decreased by -433.58% | - |
| Feb 12, 24 | -0.12 Increased by +50.79% | -0.32 Increased by +63.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 316.00 K Decreased by -3.07% | -6.13 M Decreased by -4.25% | Decreased by -1.94 K% Decreased by -7.55% |
| Jun 30, 25 | 398.00 K Increased by +314.58% | -7.60 M Decreased by -32.62% | Decreased by -1.91 K% Increased by +68.01% |
| Mar 31, 25 | 427.00 K Increased by +501.41% | -6.15 M Decreased by -16.13% | Decreased by -1.44 K% Increased by +80.69% |
| Dec 31, 24 | 185.00 K Increased by +76.19% | -2.96 M Increased by +39.73% | Decreased by -1.60 K% Increased by +65.80% |
| Sep 30, 24 | 326.00 K Increased by +503.70% | -5.88 M Decreased by -18.56% | Decreased by -1.80 K% Increased by +80.36% |
| Jun 30, 24 | 96.00 K Decreased by -13.51% | -5.73 M Increased by +11.30% | Decreased by -5.97 K% Decreased by -2.56% |
| Mar 31, 24 | 71.00 K Decreased by -18.39% | -5.29 M Increased by +30.57% | Decreased by -7.45 K% Increased by +14.93% |
| Dec 31, 23 | 105.00 K Increased by +5.15 K% | -4.91 M Increased by +39.57% | Decreased by -4.67 K% Increased by +98.85% |